Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity
暂无分享,去创建一个
J. Ball | S. K. Fehling | T. Strecker | R. Urbanowicz | S. Becker | V. von Messling | L. Kolesnikova | A. Kaufmann | V. Krähling | S. Bauer | N. Magassouba | E. Fichet-Calvet | L. Oestereich | J. Dorna | Martin Schauflinger | H. Müller | Yvonne Krebs | Verena Krähling
[1] N. Petrovsky,et al. Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. , 2020, Vaccine.
[2] Gengfu Xiao,et al. Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus , 2019, Antiviral Research.
[3] J. Armengaud,et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot , 2019, Science Translational Medicine.
[4] S. Gilbert,et al. Vaccine platforms for the prevention of Lassa fever , 2019, Immunology Letters.
[5] R. Diskin,et al. Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses , 2019, Journal of Virology.
[6] M. A. Suchard,et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak , 2019, Science.
[7] G. Gao,et al. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease , 2018, Journal of Virology.
[8] Catherine A. Freije,et al. Genomic analysis of Lassa virus from the 2018 surge in Nigeria , 2018, The New England journal of medicine.
[9] P. Jahrling,et al. Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever , 2018, Nature Communications.
[10] G. Sutter,et al. Generation of therapeutic antisera for emerging viral infections , 2018, npj Vaccines.
[11] P. Millett,et al. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts , 2018, Antiviral Research.
[12] D. Burton,et al. Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization , 2018, Immunity.
[13] Thomas Strecker,et al. Structure of the Lassa virus glycan shield provides a model for immunological resistance , 2018, Proceedings of the National Academy of Sciences.
[14] C. Picard,et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins , 2018, Journal of Virology.
[15] B. R. Noack,et al. New Lineage of Lassa Virus, Togo, 2016 , 2018, Emerging infectious diseases.
[16] J. Hubbell,et al. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. , 2017, Virology.
[17] N. Sardesai,et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever , 2017, Human vaccines & immunotherapeutics.
[18] J. Galarza,et al. Adjuvant formulations for virus-like particle (VLP) based vaccines. , 2017, Clinical immunology.
[19] Donald S. Grant,et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.
[20] R. Hewson,et al. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product , 2017, Scientific Reports.
[21] K. Chandran,et al. Structural basis for antibody-mediated neutralization of Lassa virus , 2017, Science.
[22] S. K. Fehling,et al. Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany , 2016, Genome Announcements.
[23] A. Tarr,et al. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay , 2016, The Journal of general virology.
[24] Donald S. Grant,et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. , 2016, Antiviral research.
[25] Zhìhóng Hú,et al. Virus like particle-based vaccines against emerging infectious disease viruses , 2016, Virologica Sinica.
[26] Pardis C Sabeti,et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits , 2016, Nature Communications.
[27] S. Günther,et al. New Hosts of The Lassa Virus , 2016, Scientific Reports.
[28] G. Gao,et al. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection , 2016, Scientific Reports.
[29] Thomas Strecker,et al. Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike , 2016, PLoS pathogens.
[30] Paolo Meda,et al. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection , 2015, PLoS pathogens.
[31] N. Forrester,et al. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage , 2015, Front. Microbiol..
[32] Timothy K. Soh,et al. Lassa virus entry requires a trigger-induced receptor switch , 2014, Science.
[33] S. Günther,et al. Infection of Type I Interferon Receptor-Deficient Mice with Various Old World Arenaviruses: A Model for Studying Virulence and Host Species Barriers , 2013, PloS one.
[34] A. Varki,et al. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation , 2012, Biotechnology & genetic engineering reviews.
[35] J. York,et al. The Curious Case of Arenavirus Entry, and Its Inhibition , 2012, Viruses.
[36] Y. Kawaoka,et al. Identification of Cell Surface Molecules Involved in Dystroglycan-Independent Lassa Virus Cell Entry , 2011, Journal of Virology.
[37] M. Buchmeier,et al. Glycosylation modulates arenavirus glycoprotein expression and function. , 2011, Virology.
[38] K. Schlie,et al. Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail , 2010, FEBS letters.
[39] F. J. Geske,et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever , 2010, Virology Journal.
[40] K. Schlie,et al. Viral Protein Determinants of Lassa Virus Entry and Release from Polarized Epithelial Cells , 2010, Journal of Virology.
[41] Marc Daigneault,et al. The Identification of Markers of Macrophage Differentiation in PMA-Stimulated THP-1 Cells and Monocyte-Derived Macrophages , 2010, PloS one.
[42] K. Schlie,et al. Characterization of Lassa Virus Glycoprotein Oligomerization and Influence of Cholesterol on Virus Replication , 2009, Journal of Virology.
[43] H. Klenk,et al. Inhibition of Lassa Virus Glycoprotein Cleavage and Multicycle Replication by Site 1 Protease-Adapted α1-Antitrypsin Variants , 2009, PLoS neglected tropical diseases.
[44] R. Compans,et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. , 2009, Virology.
[45] H. Klenk,et al. Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. , 2007, The Journal of general virology.
[46] David A. Anderson,et al. Virus-like particles: Passport to immune recognition , 2006, Methods.
[47] W. Garten,et al. The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C , 2006, Virology Journal.
[48] V. Deubel,et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. , 2006, Virology.
[49] I. Lukashevich,et al. A Live Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia Viruses , 2005, Journal of Virology.
[50] J. York,et al. Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junín arenavirus envelope glycoprotein , 2005, Virology.
[51] B. Mothé,et al. Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.
[52] M. Buchmeier,et al. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. , 2005, Virology.
[53] J. Auwerx,et al. The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation , 1991, Experientia.
[54] M. Aman,et al. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. , 2004, Vaccine.
[55] H. Feldmann,et al. Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.
[56] M. Georges-Courbot,et al. Lassa Virus Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to Activate Cells1 , 2004, The Journal of Immunology.
[57] M. Mohamadzadeh,et al. Ebola virus-like particles protect from lethal Ebola virus infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[58] W. Weissenhorn,et al. Lassa Virus Z Protein Is a Matrix Protein and Sufficient for the Release of Virus-Like Particles , 2003, Journal of Virology.
[59] W. Garten,et al. Signal peptide of Lassa virus glycoprotein GP‐C exhibits an unusual length , 2003, FEBS letters.
[60] W. Garten,et al. Endoproteolytic Processing of the Lymphocytic Choriomeningitis Virus Glycoprotein by the Subtilase SKI-1/S1P , 2003, Journal of Virology.
[61] N. Seidah,et al. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[62] H. Feldmann,et al. Identification of a Novel Consensus Sequence at the Cleavage Site of the Lassa Virus Glycoprotein , 2000, Journal of Virology.
[63] L. Hutwagner,et al. Effective Vaccine for Lassa Fever , 2000, Journal of Virology.
[64] Stuart T. Nichol,et al. Genetic Diversity among Lassa Virus Strains , 2000, Journal of Virology.
[65] K. Campbell,et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. , 1998, Science.
[66] J. McCormick,et al. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys , 1992, Journal of medical virology.
[67] H. Niwa,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.
[68] M. Buchmeier,et al. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus , 1990, Virology.
[69] L. Brammer,et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[70] J. B. McCormick,et al. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. , 1988, BMJ.
[71] E. S. Smith,et al. A prospective study of the epidemiology and ecology of Lassa fever. , 1987, The Journal of infectious diseases.
[72] J. McCormick. Epidemiology and control of Lassa fever. , 1987, Current topics in microbiology and immunology.
[73] J. McCormick,et al. Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. , 1986, Virology.
[74] J. McCormick,et al. Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.
[75] P. Jahrling,et al. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. , 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[76] P. Jahrling,et al. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain , 1984, Infection and immunity.
[77] P. Jahrling,et al. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. , 1984, The Journal of infectious diseases.
[78] J. Frame,et al. The use of Lassa fever convalescent plasma in Nigeria. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[79] P. Jahrling. Protection of lassa virus‐infected guinea pigs with lassa‐immune plasma of guinea pig, primate, and human origin , 1983, Journal of medical virology.